At UGA Biopharma, we’re proud to be actively contributing to the worldwide effort against rare diseases.
We’ve addressed the worldwide need for replacement enzyme therapy in two rare conditions: Pompe disease, causing progressive weakness in the heart and skeletal muscles, and Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome), a progressive condition affecting various tissues and organs.
The recombinant enzymes Alglucosidase alfa and Galsulfase are two crucial enzymes currently used for replacement therapy in Pompe disease and Mucopolysaccharidosis type VI, respectively.
At UGA Biopharma, we have developed CHO cell lines able to express Alglucosidase alfa, and Galsulfase. These cell lines are now available as Ready-to-Use, and for partners, they can make easier and shorter the way to patient treatment.
Our development includes an optimized production process in bioreactors (upstream processing) and an optimized purification process (downstream processing), supported by analytical data using state-of-the-art methodologies.
Please contact us for more information and explore more Ready-to-Use cell lines from our library visiting: https://ugabiopharma.com/r2u-cells/
#RareDisease #PompeDisease #MPSVI #biosimilars #biologics #UGABiopharma
